Phase III Trial Finds Many People With Advanced Kidney Cancer Do Not Need Surgery

For immediate release
June 3, 2018

MEDIA CONTACT:
Alise Fisher
571-483-1354
alise.fisher@asco.org

PATIENT AND CAREGIVER INQUIRIES:
Contact Cancer.Net

ASCO Perspective

“Thanks to this research, many patients with advanced kidney cancer can be spared unnecessary surgery and a host of severe side effects that often accompany it. These findings will likely lead to a dramatic change in treatment for people who are diagnosed with metastatic kidney cancer,” said ASCO Expert Sumanta K. Pal, MD.

CHICAGO – A randomized phase III clinical trial showed that many people with advanced kidney cancer can avoid surgery to remove the kidney (nephrectomy), without compromising survival. The median overall survival for people who received only the targeted therapy sunitinib (Sutent®) was 18.4 months, compared to 13.9 months for those who received surgery followed by sunitinib, the current standard of care.
These findings will be presented in ASCO’s Plenary Session, which features four studies deemed to have the greatest potential impact on patient care, out of the more than 5,800 abstracts featured as part of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

“Until now, nephrectomy has been considered the standard of care for patients with kidney cancer who have metastatic disease when the cancer is first diagnosed. These cases account for about 20% of all kidney cancers worldwide,” said lead study author Arnaud Mejean, MD, a urologist at the Department of Urology, Hôpital Européen Georges-Pompidou - Paris Descartes University in Paris, France. “Our study is the first to question the need for surgery in the era of targeted therapies and clearly shows that surgery for certain people with kidney cancer should no longer be the standard of care.”

In addition to putting patients at risk for complications, including blood loss, infection, pulmonary embolism, and heart problems, nephrectomy delays medical treatment for people with advanced kidney cancer for weeks. In some cases, the cancer worsens so rapidly during this delay that there is no time to start systemic treatment.

**About the Study**

The Carmena trial enrolled 450 patients with synchronous metastatic renal cell carcinoma (mRCC), meaning that metastases were already present when kidney cancer was first diagnosed. An estimated 40,000 to 50,000 people each year are diagnosed with this type of cancer.

The patients were randomly assigned to receive surgery followed by sunitinib or sunitinib alone. In the surgery group, patients started sunitinib 4-6 weeks after surgery to allow time for recovery from surgery.

**Key Findings**

Patients were followed for a median time of 50.9 months. Survival was not worse with sunitinib alone than with surgery and sunitinib. This was true for the study population as a whole (median survival was 18.4 months without surgery vs. 13.9 months with surgery), as well as for subgroups with an intermediate (median survival was 23.4 months vs. 19 months)
and poor prognosis (median survival was 13.3 months vs. 10.2 months) groups.

The difference in median survival seems to suggest a greater benefit with sunitinib alone. However, this cannot be concluded, as this trial was not designed to prove that one treatment is superior to the other, noted Dr. Mejean.

The rate of tumor response to therapy (tumor shrinkage) was the same in the two treatment groups (27.4% and 29.1%) and the median time until the cancer worsened was slightly longer for patients who received sunitinib alone compared with those who also had surgery (8.3 months vs. 7.2 months). Clinical benefit was experienced by 47.9% of patients treated with sunitinib only, compared with 36.6% of patients treated by surgery and sunitinib.

The authors remarked that kidney surgery is still the gold standard for people who do not need systemic therapy, such as those with only one metastasis. Those patients were not included in this clinical trial.

Next Steps
Some patients in the study had a very good response to sunitinib alone and received surgery after completing systemic treatment. The researchers plan to continue following outcomes in these patients, as well as in other subgroups of study participants. Genomic research on tumor tissue collected on the study is underway.

This study received funding from PHRC (French governmental grants for clinical research).

Study at a Glance

<table>
<thead>
<tr>
<th>Disease</th>
<th>Metastatic Kidney Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial Phase, Type</td>
<td>Phase III, Randomized</td>
</tr>
<tr>
<td>Patients on Trial</td>
<td>450</td>
</tr>
<tr>
<td>Intervention Tested</td>
<td>Surgery followed by sunitinib (standard of care) vs. sunitinib alone</td>
</tr>
<tr>
<td>Primary Finding</td>
<td>mOS 13.9 months with standard of care vs. 18.4 months with sunitinib alone</td>
</tr>
</tbody>
</table>
Secondary Finding(s)
View the full abstract.

mPFS 8.3 months with standard of care vs. 7.2 months with sunitinib alone

For your readers:

- Guide to Kidney Cancer (Cáncer de riñón)
- Understanding Targeted Therapy (Qué es la terapia dirigida)
- What is Cancer Surgery? (Qué es la cirugía oncológica)

View the disclosures for the 2018 ASCO Annual Meeting News Planning Team.

ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.

###


About ASCO:
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.